| Myriad beats Street 1Q forecasts | |
| | |
|
SALT LAKE CITY (AP) _ Myriad Genetics Inc. (MYGN) on Tuesday reported fiscal first-quarter earnings of $26.6 million.
The Salt Lake City-based company said it had net income of 37 cents per share. Earnings, adjusted for amortization costs, were 41 cents per share.
The results surpassed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of 35 cents per share.
The molecular diagnostic company posted revenue of $183.5 million in the period, which also topped Street forecasts. Five analysts surveyed by Zacks expected $178.2 million.
For the current quarter ending in January, Myriad expects its per-share earnings to range from 40 cents to 42 cents.
The company said it expects revenue in the range of $188 million to $190 million for the fiscal second quarter.
Myriad expects full-year earnings in the range of $1.60 to $1.65 per share, with revenue ranging from $750 million to $770 million.
Myriad shares have increased 24 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $42.32, a climb of 7 percent in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYGN at http://www.zacks.com/ap/MYGN
_____
Keywords: Myriad Genetics, Earnings Report
|
|
| |
ProfilIndicateurs de MarchéVALEUR : Projets & res.Communiqués de PresseRapport annuelRISQUE : Profile actifsContactez la cie |
Myriad Genetics est une société basée aux Etats-Unis D'Amerique. Myriad Genetics est cotée aux Etats-Unis D'Amerique. Sa capitalisation boursière aujourd'hui est 1,7 milliards US$ (1,6 milliards €). La valeur de son action a atteint son plus bas niveau récent le 29 mai 1998 à 10,00 US$, et son plus haut niveau récent le 17 novembre 2000 à 94,06 US$. Myriad Genetics possède 68 090 000 actions en circulation. |